glp-1 obesity drug news today september 2025 New Daily Weight Loss Pill Aims to Take on Ozempic The first of three of
Description
Comparative trials show that long-acting medications (exenatide once weekly, liraglutide, dulaglutide, and semaglutide) provide better glycemic control than short-acting medications (exenatide twice daily and lixisenatide) [90]
Tissue Barriers
LY3298176, a novel long-acting GIP/GLP-1 coagonist, shows enhanced activity on weight loss and energy utilization whilst maintaining its efficacy for glycaemic control
Optum Rx has also introduced a host of changes to ensure GLP-1 drugs are used responsibly, including optional utilization management (UM) and enhanced system edits
Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis
Well, our liver loves to create some glucose when it senses glucagon
